1. Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA 
Nawar Hanna, Quoc-Dien Trinh, Thomas Seisen, Malte W. Vetterlein, Jesse Sammon, Mark A. Preston, Stuart R. Lipsitz, Joaquim Bellmunt, Mani Menon, Toni K. Choueiri, Firas Abdollah 
European Urology Oncology 
Volume 1, Issue 1, Pages (May 2018)
DOI: /j.euo
Copyright © 2018 European Association of Urology Terms and Conditions

2. Fig. 1
Flowchart showing patient selection from the National Cancer Data Base (NCDB)between 2004 and BCa=bladder cancer; CCI=Charlson comorbidity index; ICD=International Classification of Diseases; NAC=neoadjuvant chemotherapy; PUF=participant user file; RC=radical cystectomy.
European Urology Oncology 2018 1, 83-90DOI: ( /j.euo )
Copyright © 2018 European Association of Urology Terms and Conditions

3. Fig. 2
Kaplan-Meier estimates of overall survival following radical cystectomy (RC) for patients undergoing neoadjuvant chemotherapy (NAC and RC and those undergoing RC alone according to the National Cancer Data Base between 2004 and (A) Unadjusted estimates; (B) estimates adjusted using the inverse probability of treatment weighting; and (C) sensitivity analysis with follow-up defined as time since RC.
European Urology Oncology 2018 1, 83-90DOI: ( /j.euo )
Copyright © 2018 European Association of Urology Terms and Conditions